Cargando…
Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma
BACKGROUND: Patients with recurrent or locally advanced head and neck squamous cell carcinoma (HNSCC) typically have limited treatment options and poor prognosis. AIM: To evaluate the efficacy and safety of two drugs with potent radio-sensitization properties including gemcitabine and nedaplatin as...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048568/ https://www.ncbi.nlm.nih.gov/pubmed/35611190 http://dx.doi.org/10.12998/wjcc.v10.i11.3414 |
_version_ | 1784695958731227136 |
---|---|
author | Huo, Rui-Xue Jin, Ying-Ying Zhuo, Yong-Xue Ji, Xiao-Tong Cui, Yu Wu, Xiao-Jing Wang, Yi-Jia Zhang, Long Zhang, Wen-Hua Cai, Yu-Mei Zheng, Cheng-Cheng Cui, Rui-Xue Wang, Qian-Ye Sun, Zhen Wang, Feng-Wei |
author_facet | Huo, Rui-Xue Jin, Ying-Ying Zhuo, Yong-Xue Ji, Xiao-Tong Cui, Yu Wu, Xiao-Jing Wang, Yi-Jia Zhang, Long Zhang, Wen-Hua Cai, Yu-Mei Zheng, Cheng-Cheng Cui, Rui-Xue Wang, Qian-Ye Sun, Zhen Wang, Feng-Wei |
author_sort | Huo, Rui-Xue |
collection | PubMed |
description | BACKGROUND: Patients with recurrent or locally advanced head and neck squamous cell carcinoma (HNSCC) typically have limited treatment options and poor prognosis. AIM: To evaluate the efficacy and safety of two drugs with potent radio-sensitization properties including gemcitabine and nedaplatin as concurrent chemoradiotherapy regimens in treating HNSCC. METHODS: This single-arm prospective study enrolled patients with HNSCC to receive gemcitabine on days 1 and 8 and nedaplatin on days 1 to 3 for 21 days. Intensity-modulated radiation therapy with a conventional fraction was delivered 5 days per week. Objective response rate (ORR), disease control rate, and toxicity were observed as primary endpoints. Overall survival (OS) and progression free survival were recorded and analyzed as secondary endpoints. RESULTS: A total of 24 patients with HNSCC were enrolled. During the median 22.4-mo follow-up, both ORR and disease control rate were 100%. The one-year OS was 75%, and one-year progression-free survival (PFS) was 66.7% (median PFS was 15.1 mo). Recurrent HNSCC patients had a poorer prognosis than the treatment-naïve patients, and patients who achieved complete response had better survival than those in the PR group (all P < 0.05). The most common grade 1-4 (100%) or grade 3-4 toxicities (75%) were hematological, and the most common grade 3-4 non-hematological toxicity was mucositis in 17 (71%) patients. CONCLUSION: Gemcitabine plus nedaplatin with concurrent chemoradiotherapy is a therapeutic option for HNSCC with predictable tolerability. Considering the high adverse event rate, the optimized dose and schedule must be further explored. |
format | Online Article Text |
id | pubmed-9048568 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-90485682022-05-23 Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma Huo, Rui-Xue Jin, Ying-Ying Zhuo, Yong-Xue Ji, Xiao-Tong Cui, Yu Wu, Xiao-Jing Wang, Yi-Jia Zhang, Long Zhang, Wen-Hua Cai, Yu-Mei Zheng, Cheng-Cheng Cui, Rui-Xue Wang, Qian-Ye Sun, Zhen Wang, Feng-Wei World J Clin Cases Clinical Trials Study BACKGROUND: Patients with recurrent or locally advanced head and neck squamous cell carcinoma (HNSCC) typically have limited treatment options and poor prognosis. AIM: To evaluate the efficacy and safety of two drugs with potent radio-sensitization properties including gemcitabine and nedaplatin as concurrent chemoradiotherapy regimens in treating HNSCC. METHODS: This single-arm prospective study enrolled patients with HNSCC to receive gemcitabine on days 1 and 8 and nedaplatin on days 1 to 3 for 21 days. Intensity-modulated radiation therapy with a conventional fraction was delivered 5 days per week. Objective response rate (ORR), disease control rate, and toxicity were observed as primary endpoints. Overall survival (OS) and progression free survival were recorded and analyzed as secondary endpoints. RESULTS: A total of 24 patients with HNSCC were enrolled. During the median 22.4-mo follow-up, both ORR and disease control rate were 100%. The one-year OS was 75%, and one-year progression-free survival (PFS) was 66.7% (median PFS was 15.1 mo). Recurrent HNSCC patients had a poorer prognosis than the treatment-naïve patients, and patients who achieved complete response had better survival than those in the PR group (all P < 0.05). The most common grade 1-4 (100%) or grade 3-4 toxicities (75%) were hematological, and the most common grade 3-4 non-hematological toxicity was mucositis in 17 (71%) patients. CONCLUSION: Gemcitabine plus nedaplatin with concurrent chemoradiotherapy is a therapeutic option for HNSCC with predictable tolerability. Considering the high adverse event rate, the optimized dose and schedule must be further explored. Baishideng Publishing Group Inc 2022-04-16 2022-04-16 /pmc/articles/PMC9048568/ /pubmed/35611190 http://dx.doi.org/10.12998/wjcc.v10.i11.3414 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Clinical Trials Study Huo, Rui-Xue Jin, Ying-Ying Zhuo, Yong-Xue Ji, Xiao-Tong Cui, Yu Wu, Xiao-Jing Wang, Yi-Jia Zhang, Long Zhang, Wen-Hua Cai, Yu-Mei Zheng, Cheng-Cheng Cui, Rui-Xue Wang, Qian-Ye Sun, Zhen Wang, Feng-Wei Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
title | Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
title_full | Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
title_fullStr | Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
title_full_unstemmed | Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
title_short | Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
title_sort | concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma |
topic | Clinical Trials Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048568/ https://www.ncbi.nlm.nih.gov/pubmed/35611190 http://dx.doi.org/10.12998/wjcc.v10.i11.3414 |
work_keys_str_mv | AT huoruixue concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT jinyingying concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT zhuoyongxue concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT jixiaotong concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT cuiyu concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT wuxiaojing concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT wangyijia concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT zhanglong concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT zhangwenhua concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT caiyumei concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT zhengchengcheng concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT cuiruixue concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT wangqianye concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT sunzhen concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma AT wangfengwei concurrentchemoradiotherapyusinggemcitabineandnedaplatininrecurrentorlocallyadvancedheadandnecksquamouscellcarcinoma |